cefilavancin (TD-1792) / R-Pharm, Zymeworks - LARVOL DELTA

Isatin-based Strategies for Microbial Infections: A Multifaceted Perspective. (PubMed, Rev Recent Clin Trials) - "The clinical approval of numerous isatin-based drugs, including sunitinib and nintedanib, for the treatment of cancer, as well as the evaluation of other drugs, like TD-1792 and Ro 23-9424, for the treatment of infectious diseases, demonstrate the translational success of this scaffold. This review focuses on significant advancements, procedures, and potential treatments in isatin-based antimicrobial research."

Journal • Infectious Disease • Oncology

Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates. (PubMed, Front Chem) - "The multi-targeted TD-1792, for instance, retained potent antibacterial activities against multiple strains that are resistant to its constituent, vancomycin...DSTA4637S is a pioneer antibacterial agent under clinical development and represents a novel class of bacterial therapy, that is, antibody-antibiotic conjugates. DSTA4637S is effective against the notorious persistent S. aureus bacteremia, a revelation of the abracadabra potential of antibiotic hybrid approaches."

Clinical • Journal • Review • Infectious Disease